| Title |
Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?
|
|---|---|
| Published in |
European Journal of Clinical Microbiology & Infectious Diseases, August 2014
|
| DOI | 10.1007/s10096-014-2208-6 |
| Pubmed ID | |
| Authors |
A. Torres, P. Bonanni, W. Hryniewicz, M. Moutschen, R. R. Reinert, T. Welte |
| Abstract |
Individuals <2 years and ≥50 years of age, as well as those with other specific risk factors, are especially vulnerable to invasive pneumococcal disease (IPD). Conjugate vaccines have been developed against encapsulated bacteria such as Streptococcus pneumoniae to provide improved immune responses. The 7-valent pneumococcal conjugate vaccine (PCV7) has significantly reduced the burden of vaccine-type pneumococcal diseases in children, including invasive disease and pneumonia and acute otitis media. There have also been significant declines in antimicrobial resistance in 7-valent vaccine serotypes and carriage of S. pneumoniae in the post-PCV7 era. Two to three years after the introduction of PCV13, there is emerging, global evidence of a reduced burden of pneumococcal diseases in children, including declines in IPD (UK and Germany) and nasopharyngeal carriage of PCV13 serotypes (Portugal and France). The functional immunogenicity of PCV13 in individuals ≥50 years of age has been demonstrated in clinical trials in comparison with the 23-valent pneumococcal polysaccharide vaccine and for children and adults 6 to 49 years of age. Between 2011 and 2013, PCV13 received market authorisation by the European Medicines Agency (EMA) for these additional age groups and is now available in Europe for the prevention of pneumococcal disease in all age groups. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Scientists | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 157 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| United States | 1 | <1% |
| Kenya | 1 | <1% |
| Unknown | 154 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 26 | 17% |
| Student > Ph. D. Student | 21 | 13% |
| Student > Master | 20 | 13% |
| Student > Bachelor | 16 | 10% |
| Other | 15 | 10% |
| Other | 27 | 17% |
| Unknown | 32 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 60 | 38% |
| Agricultural and Biological Sciences | 19 | 12% |
| Immunology and Microbiology | 9 | 6% |
| Nursing and Health Professions | 5 | 3% |
| Biochemistry, Genetics and Molecular Biology | 4 | 3% |
| Other | 25 | 16% |
| Unknown | 35 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2015.
All research outputs
#15,314,171
of 22,776,824 outputs
Outputs from European Journal of Clinical Microbiology & Infectious Diseases
#1,866
of 2,769 outputs
Outputs of similar age
#136,294
of 235,677 outputs
Outputs of similar age from European Journal of Clinical Microbiology & Infectious Diseases
#16
of 30 outputs
Altmetric has tracked 22,776,824 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,769 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 235,677 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.